Study of Glutamine as Prophylaxis for Irinotecan Induced Diarrhea
- First Posted Date
- 2005-11-18
- Last Posted Date
- 2016-02-25
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 130
- Registration Number
- NCT00255229
- Locations
- π¨π¦
Cross Cancer Institute, Edmonton, Alberta, Canada
Magnetic Resonance Spectroscopic Imaging (MRS) and Tumor Perfusion of Human Glioblastoma Treated With Concurrent Radiation Therapy and Temozolomide
Phase 1
Completed
- Conditions
- GlioblastomaGlioma
- First Posted Date
- 2005-11-08
- Last Posted Date
- 2016-02-24
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 26
- Registration Number
- NCT00250211
- Locations
- π¨π¦
Cross Cancer Institute, Edmonton, Alberta, Canada
Trial of Combined Aerobic and Resistance Exercise in Breast Cancer Survivors
Phase 3
Completed
- Conditions
- Breast Cancer
- Interventions
- Behavioral: Physical exercise
- First Posted Date
- 2005-11-07
- Last Posted Date
- 2016-07-18
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 301
- Registration Number
- NCT00249015
- Locations
- π¨π¦
Cross Cancer Institute, Edmonton, Alberta, Canada
MVCT Imaging Pilot Study Using Helical Tomotherapy
Completed
- Conditions
- Cancer, Carcinoma
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2016-02-24
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 16
- Registration Number
- NCT00168142
- Locations
- π¨π¦
Cross Cancer Institute, Edmonton, Alberta, Canada
Xerostomia in Head and Neck Cancer Patients Receiving Radiation as the Primary Treatment Versus Patients Who Will Not Have Such a Procedure
Phase 2
Completed
- Conditions
- Head and Neck Cancer
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2016-02-24
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 42
- Registration Number
- NCT00168116
- Locations
- π¨π¦
Cross Cancer Institute, Edmonton, Alberta, Canada
Investigating the Therapeutic Effectiveness of Aloe Barbadensis in Reducing Cutaneous Side-Effects of Radiation Treatment for Breast Cancer.
Phase 3
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2017-01-24
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 231
- Registration Number
- NCT00156806
- Locations
- π¨π¦
Cross Cancer Institute, Edmonton, Alberta, Canada
Angiogenic Profile and Non-invasive Imaging May Predict Tumor Progression of High Risk Group Low Grade Glioma (LGG)
Completed
- Conditions
- Glioma
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2016-02-26
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 10
- Registration Number
- NCT00137488
- Locations
- π¨π¦
Cross Cancer Institute, Edmonton, Alberta, Canada
Using Intensity-Modulated Radiation Therapy to Permit Sparing of Parotid Gland Function
Phase 1
Completed
- Conditions
- Head and Neck Cancer
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2016-02-26
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 130
- Registration Number
- NCT00137475
- Locations
- π¨π¦
Cross Cancer Institute, Edmonton, Alberta, Canada
Cisplatin, Carboplatin, and Oxaliplatin Interactions With Plasma Proteins
Terminated
- Conditions
- Colorectal CancerLung Cancer
- First Posted Date
- 2005-08-19
- Last Posted Date
- 2016-02-26
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 100
- Registration Number
- NCT00131586
- Locations
- π¨π¦
Cross Cancer Institute, Edmonton, Alberta, Canada
Thymidylate Synthase Polymorphisms as a Predictor of Toxicity to 5-Fluorouracil Based Chemotherapy in Stage III Colon Cancer
- Conditions
- Colon Cancer
- First Posted Date
- 2005-08-19
- Last Posted Date
- 2017-01-16
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 104
- Registration Number
- NCT00131599
- Locations
- π¨π¦
Cross Cancer Institute, Edmonton, Alberta, Canada
Β© Copyright 2025. All Rights Reserved by MedPath